News Sentiment

GDTC sentiment intelligence

CytoMed Therapeutics Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.03 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+5.6% over one week, -9.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 5.6% Price confirming higher
Trend fit Trend inactive -9.6% over four weeks
Fair value -54.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
TradingKey 7
Market source 5
dars.gov.et 4
TradingView 4
Moomoo 3
Finviz 3
FinancialContent 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 13
Deals and strategy 6
Guidance 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-51 of 51
Finviz Direct company coverage

GDTC - CytoMed Therapeutics Ltd Stock Price and Quote

This article provides a detailed stock price and quote for CytoMed Therapeutics Ltd (GDTC), including its last closing price, financial metrics, and recent news. It highlights various financial data points like market cap, income, sales, and insider ownership, alongside a chronol

Tone
Positive 63/100
Event
Market update
Published
01 Jun 2026 00:14
Source
Finviz
Stock Titan Direct company coverage

CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares

CytoMed Therapeutics director Toh Keng Kiat has reported an initial beneficial ownership of 4,000 Ordinary Shares in the company. This disclosure is a routine Form 3 filing with the SEC and signifies an existing holding rather than a new transaction. The shares are directly owned

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 12:40
Source
Stock Titan
openPR.com Direct company coverage

CytoMed Therapeutics Ltd - A Rising Star in Singapore's Cancer Biotechnology Sector

CytoMed Therapeutics Ltd, a clinical-stage biotech company based in Singapore, is making significant strides in developing affordable cancer therapies using allogeneic Gamma Delta T Cells. Through strategic acquisitions and a focus on global expansion, particularly in China and I

Tone
Positive 67/100
Event
Deals and strategy
Published
21 May 2026 10:40
Source
openPR.com
openPR.com Direct company coverage

CytoMed Therapeutics Limited is accelerating its international expansion

CytoMed Therapeutics Limited is expanding its international presence, starting with a name change for its subsidiary to CytoMed International Pte. Ltd. The company aims to explore global opportunities, particularly in Asia and China, through potential joint ventures and medical t

Tone
Positive 70/100
Event
Market update
Published
18 May 2026 05:39
Source
openPR.com
Stock Titan Direct company coverage

[Form 3] CytoMed Therapeutics Ltd Initial Statement of Beneficial Ownership

CytoMed Therapeutics Ltd's Chief Corporate Officer, Tan Yoong Ying, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 25,781 Ordinary Shares with no par value. This SEC filing indicates his existing stake without any recent purchase or

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership

CytoMed Therapeutics director Choo Chee Kong filed an initial Form 3 detailing his beneficial ownership in the company. The filing reports direct ownership of 318,324 Ordinary Shares and indirect ownership through Glorious Finance Limited (2,075,310 shares) and EP Capital Inc. (1

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 13:10
Source
Stock Titan
Stock Titan Direct company coverage

CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares

CytoMed Therapeutics' CFO, Yvonne Goh, has filed an initial insider ownership report (Form 3) showing she directly holds 25,781 Ordinary Shares in the company. This filing simply reports her existing stake and does not indicate any recent purchases, sales, or option exercises. Th

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 13:10
Source
Stock Titan
Stock Titan Direct company coverage

CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3

CytoMed Therapeutics director Yew Chak Hua has reported an initial ownership of 2,469 ordinary shares on Form 3, establishing his status as a director with a direct stake. This filing indicates current holdings upon becoming a director and does not reflect any recent buying or se

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 13:10
Source
Stock Titan
Stock Titan Direct company coverage

[144] CytoMed Therapeutics Ltd SEC Filing

This article reports on a Form 144 SEC filing by CytoMed Therapeutics Ltd (GDTC). The filing indicates a proposed sale of 117,337 ordinary shares with an aggregate market value of $98,093.73, acquired on April 22, 2021, via a share subscription from the issuer. The sale is schedu

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 14:39
Source
Stock Titan